Cargando…

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormaliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoretsanitis, Georgios, Dubath, Céline, Grosu, Claire, Piras, Marianna, Laaboub, Nermine, Ranjbar, Setareh, Ansermot, Nicolas, Crettol, Séverine, Vandenberghe, Frederik, Gamma, Franziska, von Gunten, Armin, Plessen, Kerstin Jessica, Seifritz, Erich, Conus, Philippe, Eap, Chin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305461/
https://www.ncbi.nlm.nih.gov/pubmed/35150056
http://dx.doi.org/10.1111/bcpt.13715
_version_ 1784752331126996992
author Schoretsanitis, Georgios
Dubath, Céline
Grosu, Claire
Piras, Marianna
Laaboub, Nermine
Ranjbar, Setareh
Ansermot, Nicolas
Crettol, Séverine
Vandenberghe, Frederik
Gamma, Franziska
von Gunten, Armin
Plessen, Kerstin Jessica
Seifritz, Erich
Conus, Philippe
Eap, Chin B.
author_facet Schoretsanitis, Georgios
Dubath, Céline
Grosu, Claire
Piras, Marianna
Laaboub, Nermine
Ranjbar, Setareh
Ansermot, Nicolas
Crettol, Séverine
Vandenberghe, Frederik
Gamma, Franziska
von Gunten, Armin
Plessen, Kerstin Jessica
Seifritz, Erich
Conus, Philippe
Eap, Chin B.
author_sort Schoretsanitis, Georgios
collection PubMed
description Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed‐effects logistic regression models. In 392 olanzapine‐treated patients (median age 38.0 years, interquartile range [IQR] = 26.0–53.3, median dose 10.0 mg/day, IQR = 5.0–10.0 for a median follow‐up duration of 40.0 days, IQR = 20.7–112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co‐prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57–2.97). EWG might be prominent in high‐dose olanzapine‐treated patients with treatment duration and co‐prescription of other medications being weight gain moderators. The lack of major dose‐dependent patterns for weight gain emphasizes that olanzapine‐treated patients are at weight gain risk regardless of the dose.
format Online
Article
Text
id pubmed-9305461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93054612022-07-28 Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort Schoretsanitis, Georgios Dubath, Céline Grosu, Claire Piras, Marianna Laaboub, Nermine Ranjbar, Setareh Ansermot, Nicolas Crettol, Séverine Vandenberghe, Frederik Gamma, Franziska von Gunten, Armin Plessen, Kerstin Jessica Seifritz, Erich Conus, Philippe Eap, Chin B. Basic Clin Pharmacol Toxicol Clinical Pharmacology Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed‐effects logistic regression models. In 392 olanzapine‐treated patients (median age 38.0 years, interquartile range [IQR] = 26.0–53.3, median dose 10.0 mg/day, IQR = 5.0–10.0 for a median follow‐up duration of 40.0 days, IQR = 20.7–112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co‐prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57–2.97). EWG might be prominent in high‐dose olanzapine‐treated patients with treatment duration and co‐prescription of other medications being weight gain moderators. The lack of major dose‐dependent patterns for weight gain emphasizes that olanzapine‐treated patients are at weight gain risk regardless of the dose. John Wiley and Sons Inc. 2022-02-17 2022-04 /pmc/articles/PMC9305461/ /pubmed/35150056 http://dx.doi.org/10.1111/bcpt.13715 Text en © 2022 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Pharmacology
Schoretsanitis, Georgios
Dubath, Céline
Grosu, Claire
Piras, Marianna
Laaboub, Nermine
Ranjbar, Setareh
Ansermot, Nicolas
Crettol, Séverine
Vandenberghe, Frederik
Gamma, Franziska
von Gunten, Armin
Plessen, Kerstin Jessica
Seifritz, Erich
Conus, Philippe
Eap, Chin B.
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title_full Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title_fullStr Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title_full_unstemmed Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title_short Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
title_sort olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
topic Clinical Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305461/
https://www.ncbi.nlm.nih.gov/pubmed/35150056
http://dx.doi.org/10.1111/bcpt.13715
work_keys_str_mv AT schoretsanitisgeorgios olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT dubathceline olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT grosuclaire olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT pirasmarianna olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT laaboubnermine olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT ranjbarsetareh olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT ansermotnicolas olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT crettolseverine olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT vandenberghefrederik olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT gammafranziska olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT vonguntenarmin olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT plessenkerstinjessica olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT seifritzerich olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT conusphilippe olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort
AT eapchinb olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort